Laboratory of Intensive Care, Department of Intensive Care, The Affiliated Hospital of Yangzhou University, Yangzhou, PR China.
Department of Pathology, Northern Jiangsu People's Hospital, Yangzhou, PR China.
Phytomedicine. 2024 Dec;135:156131. doi: 10.1016/j.phymed.2024.156131. Epub 2024 Oct 5.
Accumulation of senescent cells in tissues and their downstream effect programs have emerged as key drivers of aging and age-associated pathologies. Recent progresses in senotherapeutics indicated that either selectively killing senescent cells with senolytics or suppressing the senescence-associated secretory phenotype (SASP) secretion using senomorphics contributes to extending of the healthy lifespan and alleviating numerous age-related disorders in mice.
However, the potential side-effects and long-term cytotoxicity of the above novel compounds have not yet been determined. Therefore, it seems to be more efficient to explore new senotherapeutical functions from approved drugs.
The effects of valproic acid (VPA), a derivative of valine, in cellular senescence were evaluated by senescence-associated β galactosidase (SA-β-Gal) staining, flow cytometry and western blot (WB). The cell viability was tested using CCK-8 kits. Cell apoptosis was detected by Annexin V-EGFP/PI apoptosis detection kit. Cell autophagy was checked using GFP-RFP-LC3 ratiometric plasmid. The roles of VPA in lung aging were investigated by in vivo experiments using H&E and Masson staining, WB, as well as electronic microscope strategies.
Here we identified VPA was able to induce an over-accumulation of reactive oxygen species (ROS) (>1.5 times increasing) and apoptosis (>2 times increasing) of senescent cells. Mechanistically, VPA activated the phospholipid modifying enzyme membrane-bound O-acyltransferase domain-containing protein 1 (MBOAT1), which was repressed during senescence, then promoted mitochondrial autophagy and apoptosis. In addition, VPA was also found to alleviate therapy induced abnormal mitochondria and lung aging phenotype (>1.5 times decreasing of lung fibrosis markers and >2.5 times increasing of naïve/memory CD4+ or CD8+ T cells) in vivo.
Taken together, our study demonstrated that VPA was able to selectively kill senescent cells both in vitro and in vivo, and thus shedding light on new functions and novel potential application of VPA in anti-aging and anti-age-associated diseases.
组织中衰老细胞的积累及其下游效应程序已成为衰老和与年龄相关疾病的关键驱动因素。最近在衰老治疗学方面的进展表明,使用衰老细胞选择性清除剂(senolytics)选择性地杀死衰老细胞,或使用衰老模拟物(senomorphics)抑制衰老相关分泌表型(SASP)的分泌,有助于延长健康寿命并缓解小鼠的许多与年龄相关的疾病。
然而,上述新型化合物的潜在副作用和长期细胞毒性尚未确定。因此,从已批准的药物中探索新的衰老治疗功能似乎更为有效。
通过衰老相关β半乳糖苷酶(SA-β-Gal)染色、流式细胞术和蛋白质印迹(WB)评估丙戊酸(VPA),一种缬氨酸的衍生物,在细胞衰老中的作用。使用 CCK-8 试剂盒测试细胞活力。通过 Annexin V-EGFP/PI 凋亡检测试剂盒检测细胞凋亡。使用 GFP-RFP-LC3 比率质粒检查细胞自噬。通过 H&E 和 Masson 染色、WB 以及电子显微镜策略,在体内实验中研究 VPA 在肺老化中的作用。
我们发现 VPA 能够诱导衰老细胞中活性氧(ROS)(增加 1.5 倍以上)和细胞凋亡(增加 2 倍以上)的过度积累。机制上,VPA 激活了磷脂修饰酶膜结合酰基转移酶结构域蛋白 1(MBOAT1),MBOAT1 在衰老过程中受到抑制,然后促进线粒体自噬和凋亡。此外,还发现 VPA 还能减轻治疗引起的异常线粒体和肺老化表型(肺纤维化标志物减少 1.5 倍以上,幼稚/记忆 CD4+或 CD8+T 细胞增加 2.5 倍以上)。
总之,我们的研究表明,VPA 能够在体外和体内选择性地杀死衰老细胞,从而为 VPA 在抗衰老和与年龄相关疾病中的新功能和新潜在应用提供了新的见解。